Below are the most recent publications written about "Multiple Sclerosis, Relapsing-Remitting" by people in Profiles.
-
Giovannoni G, Boyko A, Correale J, Edan G, Freedman MS, Montalban X, Rammohan K, Stefoski D, Yamout B, Leist T, Aydemir A, Borsi L, di Cantogno EV. A plain language summary on assessing the long-term effectiveness of cladribine tablets in people living with relapsing multiple sclerosis: The CLASSIC-MS study. Neurodegener Dis Manag. 2023 10; 13(5):261-268.
-
Kalatskaya I, Giovannoni G, Leist T, Cerra J, Boschert U, Rolfe PA. Revealing the immune cell subtype reconstitution profile in patients from the CLARITY study using deconvolution algorithms after cladribine tablets treatment. Sci Rep. 2023 05 18; 13(1):8067.
-
Giovannoni G, Boyko A, Correale J, Edan G, Freedman MS, Montalban X, Rammohan K, Stefoski D, Yamout B, Leist T, Aydemir A, Borsi L, Verdun di Cantogno E. Long-term follow-up of patients with relapsing multiple sclerosis from the CLARITY/CLARITY Extension cohort of CLASSIC-MS: An ambispective study. Mult Scler. 2023 05; 29(6):719-730.
-
Skarlis C, Markoglou N, Gontika M, Bougea A, Katsavos S, Artemiadis A, Chrousos G, Dalakas M, Stefanis L, Anagnostouli M. First-line disease modifying treatments in pediatric-onset multiple sclerosis in Greece: therapy initiation at more advanced age is the main cause of treatment failure, in a retrospective observational study, with a cohort from a single Multiple Sclerosis Center. Neurol Sci. 2023 Feb; 44(2):693-701.
-
Stefano N, Sormani MP, Giovannoni G, Rammohan K, Leist TP, Coyle PK, Dangond F, Alexandri N, Galazka A. Relapses in people with multiple sclerosis treated with cladribine tablets followed for up to 5?years: a plain language summary. Neurodegener Dis Manag. 2022 12; 12(6):303-310.
-
Kiapour N, Wu B, Wang Y, Seyedsadr M, Kapoor S, Zhang X, Elzoheiry M, Kasimoglu E, Wan Y, Markovic-Plese S. Therapeutic Effect of Anti-CD52 Monoclonal Antibody in Multiple Sclerosis and Its Animal Models Is Mediated via T Regulatory Cells. J Immunol. 2022 07 01; 209(1):49-56.
-
Fadul CE, Mao-Draayer Y, Ryan KA, Noelle RJ, Wishart HA, Channon JY, Kasper IR, Oliver B, Mielcarz DW, Kasper LH. Safety and Immune Effects of Blocking CD40 Ligand in Multiple Sclerosis. Neurol Neuroimmunol Neuroinflamm. 2021 11; 8(6).
-
Gontika M, Skarlis C, Markoglou N, Evangelopoulos ME, Velonakis G, Chrousos GP, Dalakas M, Stefanis L, Anagnostouli M. Fingolimod as a first- or second-line treatment in a mini-series of young Hellenic patients with adolescent-onset multiple sclerosis: focus on immunological data. Neurol Sci. 2022 Apr; 43(4):2641-2649.
-
Weinstock-Guttman B, Bermel R, Cutter G, Freedman MS, Leist TP, Ma X, Kile D, Musch B, Reder AT, Wolinsky JS. Ocrelizumab treatment for relapsing-remitting multiple sclerosis after a suboptimal response to previous disease-modifying therapy: A nonrandomized controlled trial. Mult Scler. 2022 04; 28(5):790-800.
-
Anagnostouli MC, Velonakis G, Dalakas MC. Aggressive Herpes Zoster in Young Patients With Multiple Sclerosis Under Dimethyl Fumarate: Significance of CD8+ and Natural Killer Cells. Neurol Neuroimmunol Neuroinflamm. 2021 07; 8(4).